MCCLAIN C HADDOW

LDA lobbyist id 68662. Registrants reported 3 convictions under this id, restated across 30 entries on 30 LD-2 filings.

Disclosed by the registrant on the LD-2, as the Honest Leadership and Open Government Act requires. The text is the registrant's own, reproduced as filed. Open America does not verify it against court records.

Convictions reported under this id

September 15, 1987 Restated on 6 filings

U.S. District Court, 18 U.S.C. Section 208(a), conflict of interest (2 counts)

As filed by UPSTREAM CONSULTING for ZIONS THERAPEUTICS, 2nd Quarter (Apr 1 - June 30) 2026. Filing on Open America · Official LD-2 document

September 15, 1987 Restated on 19 filings

9/15/1987, U.S. District Court, 18 U.S.C. Section 208(a), conflict of interest (2 counts)

As filed by UPSTREAM CONSULTING for RARE ACCESS ACTION PROJECT, 2nd Quarter (Apr 1 - June 30) 2026. Filing on Open America · Official LD-2 document

September 15, 1987 Restated on 5 filings

18 U.S.C. Section 208(a), conflict of interest (2 counts)

As filed by UPSTREAM CONSULTING for MANAGEMENT & TRAINING CORPORATION, 2nd Quarter (Apr 1 - June 30) 2026. Filing on Open America · Official LD-2 document

Filings carrying a disclosure under this id 30

Posted	Registrant	Client	Period
Jul 17, 2026	UPSTREAM CONSULTING	ZIONS THERAPEUTICS	2nd Quarter (Apr 1 - June 30) 2026	Filing →
Jul 17, 2026	UPSTREAM CONSULTING	RARE ACCESS ACTION PROJECT	2nd Quarter (Apr 1 - June 30) 2026	Filing →
Jul 17, 2026	UPSTREAM CONSULTING	PRIMUS PHARMACEUTICAL	2nd Quarter (Apr 1 - June 30) 2026	Filing →
Jul 17, 2026	UPSTREAM CONSULTING	AMERICAN KRATOM ASSOCIATION	2nd Quarter (Apr 1 - June 30) 2026	Filing →
Jul 17, 2026	UPSTREAM CONSULTING	MANAGEMENT & TRAINING CORPORATION	2nd Quarter (Apr 1 - June 30) 2026	Filing →
May 4, 2026	UPSTREAM CONSULTING	ZIONS THERAPEUTICS	1st Quarter (Jan 1 - Mar 31) 2026	Filing →
May 4, 2026	UPSTREAM CONSULTING	RARE ACCESS ACTION PROJECT	1st Quarter (Jan 1 - Mar 31) 2026	Filing →
May 4, 2026	UPSTREAM CONSULTING	PRIMUS PHARMACEUTICAL	1st Quarter (Jan 1 - Mar 31) 2026	Filing →
May 4, 2026	UPSTREAM CONSULTING	AMERICAN KRATOM ASSOCIATION	1st Quarter (Jan 1 - Mar 31) 2026	Filing →
May 4, 2026	UPSTREAM CONSULTING	MANAGEMENT & TRAINING CORPORATION	1st Quarter (Jan 1 - Mar 31) 2026	Filing →
Jan 30, 2026	UPSTREAM CONSULTING	ZIONS THERAPEUTICS	4th Quarter (Oct 1 - Dec 31) 2025	Filing →
Jan 30, 2026	UPSTREAM CONSULTING	RARE ACCESS ACTION PROJECT	4th Quarter (Oct 1 - Dec 31) 2025	Filing →
Jan 30, 2026	UPSTREAM CONSULTING	PRIMUS PHARMACEUTICAL	4th Quarter (Oct 1 - Dec 31) 2025	Filing →
Jan 30, 2026	UPSTREAM CONSULTING	AMERICAN KRATOM ASSOCIATION	4th Quarter (Oct 1 - Dec 31) 2025	Filing →
Jan 30, 2026	UPSTREAM CONSULTING	MANAGEMENT & TRAINING CORPORATION	4th Quarter (Oct 1 - Dec 31) 2025	Filing →
Oct 25, 2025	UPSTREAM CONSULTING	ZIONS THERAPEUTICS	3rd Quarter (July 1 - Sep 30) 2025	Filing →
Oct 25, 2025	UPSTREAM CONSULTING	RARE ACCESS ACTION PROJECT	3rd Quarter (July 1 - Sep 30) 2025	Filing →
Oct 25, 2025	UPSTREAM CONSULTING	PRIMUS PHARMACEUTICAL	3rd Quarter (July 1 - Sep 30) 2025	Filing →
Oct 25, 2025	UPSTREAM CONSULTING	AMERICAN KRATOM ASSOCIATION	3rd Quarter (July 1 - Sep 30) 2025	Filing →
Oct 25, 2025	UPSTREAM CONSULTING	MANAGEMENT & TRAINING CORPORATION	3rd Quarter (July 1 - Sep 30) 2025	Filing →
Aug 1, 2025	UPSTREAM CONSULTING	ZIONS THERAPEUTICS	2nd Quarter (Apr 1 - June 30) 2025	Filing →
Aug 1, 2025	UPSTREAM CONSULTING	RARE ACCESS ACTION PROJECT	2nd Quarter (Apr 1 - June 30) 2025	Filing →
Aug 1, 2025	UPSTREAM CONSULTING	PRIMUS PHARMACEUTICAL	2nd Quarter (Apr 1 - June 30) 2025	Filing →
Aug 1, 2025	UPSTREAM CONSULTING	AMERICAN KRATOM ASSOCIATION	2nd Quarter (Apr 1 - June 30) 2025	Filing →
Aug 1, 2025	UPSTREAM CONSULTING	MANAGEMENT & TRAINING CORPORATION	2nd Quarter (Apr 1 - June 30) 2025	Filing →

Page 1 of 2 Next

This page covers the conviction disclosures filed under LDA lobbyist id 68662. It is not a full record of the person's lobbying: the lobbyist rows on a filing carry a name but no LDA id, so the two cannot be joined without a change to how the data is stored. Source: federal Lobbying Disclosure Act LD-2 filings.